A Phase 3 interventional study of Dexmethylphenidate HCl extended-release capsules in ADHD, ADD, sponsored by Novartis. Completed at 25 sites in United States. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2007-12-21.
Sponsored by Novartis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Attention Deficit Disorder with Hyperactivity by Novartis — none open to participants now, none under way, none of them phase 3. Attention Deficit Disorder with Hyperactivity · Novartis.
Among the 10 studies in Attention Deficit Disorder with Hyperactivity by Novartis, this one is the 3rd largest by enrollment, is one of 2 that started in 2006, is one of 7 in phase 3, and was the 4th registered.
1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.
Browse Attention Deficit Disorder with Hyperactivity studies →None of the 10 studies in Attention Deficit Disorder with Hyperactivity by Novartis is open now. The open studies under Attention Deficit Disorder with Hyperactivity, anywhere →
Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.
This study: 6 Years to 12 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 252 is above the median of 71 across 1,437 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.
Median enrollment 146 across the 10 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Attention Deficit Disorder with Hyperactivity by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine which dosages of dexmethylphenidate HCl extended-release capsules may represent effective treatment for ADHD in children 6-12 years of age.
The purpose of this study is to determine which dosages of dexmethylphenidate HCl extended-release capsules may represent effective treatment for ADHD in children 6-12 years of age.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Assessment of the symptoms by the patient's teacher after 5 weeks of treatment.
Assessment of the symptoms by the patient's parent after five weeks of treatment.
Change in severity of the illness assessed by the physician after 5 weeks of treatment
Improvement of the illness assessed by the physician after 5 weeks of treatment
Safety and tolerability of 5 week's treatment with dexmethylphenidate HCl extended-release capsules in children with Attention-Deficit/Hyperactivity Disorder by assessing the frequency of adverse findings
The record gives a start of Feb 2006 and a completion of Nov 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmethylphenidate
Attention Deficit Disorder with Hyperactivity →